Tenax Therapeutics (TENX)

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.

Company profile

Anthony DiTonno
Fiscal year end
Former names
Life Newco, Inc. • PHPrecisionMed Inc. ...
IRS number

TENX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


15 May 22
2 Jul 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.87M 2.87M 2.87M 2.87M 2.87M 2.87M
Cash burn (monthly) 905.08K 55.68K (no burn) (no burn) 979.23K 881.06K
Cash used (since last report) 2.78M 170.72K n/a n/a 3M 2.7M
Cash remaining 93.47K 2.7M n/a n/a -133.89K 167.11K
Runway (months of cash) 0.1 48.5 n/a n/a -0.1 0.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Jun 22 June Sherie Almenoff Stock Option Common Stock Grant Acquire A No No 0.62 5,000 3.1K 5,000
9 Jun 22 Michael H. Davidson Stock Option Common Stock Grant Acquire A No No 0.62 5,000 3.1K 5,000
9 Jun 22 Doogan Declan Stock Option Common Stock Grant Acquire A No No 0.62 5,000 3.1K 5,000
9 Jun 22 Chrisopher Thomas Giordano Stock Option Common Stock Grant Acquire A No No 0.62 200,000 124K 200,000
9 Jun 22 Robyn Hunter Stock Option Common Stock Grant Acquire A No No 0.62 6,250 3.88K 6,250
32.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 25 17 +47.1%
Opened positions 12 4 +200.0%
Closed positions 4 12 -66.7%
Increased positions 0 2 EXIT
Reduced positions 2 2
13F shares Current Prev Q Change
Total value 6.54M 5.76M +13.7%
Total shares 8.08M 5.53M +46.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Gofen & Glossberg 3.82M $3.09M 0.0%
Armistice Capital 2.02M $1.64M NEW
Ikarian Capital 735.1K $596K NEW
BLK Blackrock 510.72K $413K -0.3%
Vanguard 358.98K $290K NEW
PNC PNC Financial Services 200K $162K 0.0%
STT State Street 138.41K $112K NEW
Boothbay Fund Management 71.81K $58K NEW
Renaissance Technologies 67.43K $55K -16.2%
Financial Advisory Service 58.33K $47K 0.0%
Largest transactions Shares Bought/sold Change
Armistice Capital 2.02M +2.02M NEW
Hudson Bay Capital Management 0 -777.2K EXIT
Ikarian Capital 735.1K +735.1K NEW
Vanguard 358.98K +358.98K NEW
STT State Street 138.41K +138.41K NEW
Boothbay Fund Management 71.81K +71.81K NEW
Renaissance Technologies 67.43K -13K -16.2%
HRT Financial 10.66K +10.66K NEW
Tower Research Capital 4.82K +4.82K NEW
BLK Blackrock 510.72K -1.57K -0.3%

Financial report summary

CytokineticsGossamer Bio

Content analysis

H.S. sophomore Avg
New words: adequate, adherence, aim, ASU, cardiopulmonary, care, caring, chain, copy, counterpart, curtail, difficult, disruption, domiciliary, enable, expand, expedited, explanatory, exploited, foundation, furniture, government, headcount, health, highly, intent, IP, kidney, kind, Label, leverage, leveraging, listing, low, modest, negative, objective, opinion, outlined, outsourcing, Pat, PCT, preceding, Premium, prepaid, prescribed, presumption, principle, promise, promising, proof, refine, removing, request, robust, saving, science, Similarly, strategy, stroke, Subtopic, supplementally, traditional, unchanged, unredacted, variant
Removed: abdominal, absorbed, accurate, acknowledged, activator, acute, acutely, addressed, adjunct, advanced, advice, afterload, Aid, ambulatory, American, amino, animal, announced, appetite, arbitration, arise, artery, assumption, assure, ATP, atrial, attributed, backward, Bank, baseline, beta, bicycle, binding, bioavailability, biological, blockade, Breakthrough, calcium, calculated, cancer, capillary, cardiac, cardiogenic, Cardiology, cardioprotective, cascade, causal, central, characterize, close, CML, combined, comorbidity, comparative, comparing, Comparison, compatibility, competitively, confirmed, confounded, congestion, consisting, contractility, conventional, criteria, CRO, cure, cytochrome, daily, damage, death, decline, decompensated, demand, demonstrate, demonstrated, denied, depending, Deregulation, desensitization, detailed, diarrhea, diastolic, differentiation, disbursed, discovered, discovery, distance, distention, diverse, dobutamine, dosing, dramatic, dysfunction, Economic, edema, efficacy, ejection, electrocardiographic, elevated, eligible, employed, employee, Encouraged, endothelin, endpoint, enrolled, entry, enzyme, ESC, estimate, European, evolving, examining, exceeding, expectation, explored, expression, extended, extensively, failed, failing, FC, filling, final, Finally, Finnish, fluid, formation, found, fraction, frequent, Functional, gastric, Gleevec, growth, halt, headache, hemodynamic, hemodynamically, HFpEF, HFrEF, history, home, Horizon, hospital, hospitalization, hospitalized, hypotension, impairment, improvement, improving, incidence, induce, induced, inhibit, inhibiting, inhibitor, initiated, inotropic, intolerance, Jebsen, journal, kinase, laboratory, lack, largely, lead, led, leg, Lender, leukemia, liver, loan, maintained, manuscript, marketed, mechanical, mechanism, mediated, metabolism, metabolite, metabolized, minimizing, mitochondrial, mmHg, monitoring, morbidity, mortality, mPAP, muscle, myeloid, myelosuppression, natriuretic, nausea, nitric, noncancer, nonclinical, notice, observed, Opening, opportunity, orphan, outpatient, output, outreach, overexpressed, oxide, PAP, partially, participated, passive, pathway, Paycheck, paying, PCWP, PDGF, PDGFRA, peptide, perfusion, pharmacologic, placebo, platelet, play, population, positive, potassium, PPP, prediction, preferable, preliminary, preload, preparing, preserve, preserved, pressure, prevalence, primary, produce, progression, projected, promissory, proposal, proposed, Protection, protein, protocol, proxy, published, pump, pyrimidine, qualified, randomized, RAP, rapid, rare, rash, receiving, reduced, regimen, regression, release, Relief, remodeling, replace, require, resistance, response, retention, reversal, reverse, revised, revolutionized, SBA, Scientific, secondary, security, sensitization, setting, shock, shorter, show, showing, signaling, Simdax, size, small, smooth, Society, specialty, specifically, sponsor, sponsored, stabilizing, statistically, stimuli, studied, sublicenseable, submission, submitted, subpart, successfully, summarize, supine, supporting, surgery, surrogate, sustained, symptomatic, systolic, test, text, therapy, thought, tired, tissue, tolerability, tolerated, trading, transition, transmission, Treasury, treat, treated, triple, troponin, type, typically, tyrosine, ultimately, unique, utilized, validated, vascular, vasculature, vasoconstriction, vasodilation, vasodilator, vasodilatory, ventricle, ventricular, vested, Virtual, vomiting, walk, wedge, week, weekly, wholly, withdraw, worldwide, worsening

Reddit threads